MedPath

Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy

Completed
Conditions
Acute Promyelocytic Leukemia
Pregnancy
Registration Number
NCT01472107
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Brief Summary

The GIMEMA FOUNDATION promotes an observational (retrospective) study on number and outcome of pregnancy in childbearing age female patients treated with chemotherapy for APL. These patients were enrolled in studies AIDA0493, AIDA2000 and were in CR.

Detailed Description

Acute promielocitic leukaemia (APL) Among all the AML subtypes, APL has the distinction of being the most curable. The median age at diagnosis is 40 years, which is younger than with other AML subtypes. The fact that APL is more common in younger patients increases the likelihood that it may occur during fertile age. The introduction of ATRA and ATO has substantially modified the outcome of APL: in two successive studies 94% of patients achieved CR and the 6-yr OS rates (PETHEMA and GIMEMA) were about 80% 2,3,6.

ATRA is highly effective in APL patients, but adverse effects such as retinoic acid syndrome, arrhythmias, headache, rash, dizziness have been reported. Moreover, retinoids are known to be potent teratogens and increased rates of spontaneous abortion and major fetal abnormalities have been reported 10. Most of the cases reported suggest that ATRA is relatively safe for both mother and fetus when used in the second and third trimesters. By contrast, when it was used in the first trimester, a negative foetal outcome was reported. No data have yet been reported on the outcomes of pregnancies in young patients with APL, occurring during CCR following ATRA-including chemotherapy regimens.

APL therapy AIDA regimen: simultaneous Atra plus IDArubicin (AIDA) combination for induction treatment, followed by 3 courses of intensive chemotherapy as consolidation2.

Consolidation therapy in the AIDA-0493 trial consisted of 3 chemotherapy courses with Ara-C and idarubicin3.

Consolidation treatment in the AIDA-2000 was given according to a risk-adapted strategy as follows: patients with low-/intermediate-risk received the same 3 consolidation courses as in the AIDA-0493 but with omission of cytarabine; patients in the high-risk group received the identical 3 cycles as in the AIDA-0493.

Study rationale This is an observational (retrospective) study on number and outcome of pregnancy in childbearing age female patients treated with chemotherapy for APL. These patients were enrolled in studies studies AIDA0493, AIDA2000 and were in CR.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
69
Inclusion Criteria
  • Patients alive aged between 18 and 50 years
  • Patients with unequivocal diagnosis of APL according to the FAB classification or WHO 2008 diagnostic criteria.

Female in childbearing age treated for APL, enrolled in the studies AIDA0493, AIDA2000 in CR after 2 years of maintenance with the exclusion of those randomized to observation in the AIDA2000, AIDA0493

Read More
Exclusion Criteria
  • Patients aged < 18 and > 50 years;
  • Patients receiving chemotherapy;
  • Concomitant psychiatric disorder that would interfere or prevent the subject from participating in the study.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Description of pregnanciesAt 24 monhts from study entry

The primary objective is to describe pregnancies in female patients treated with AIDA0493, AIDA2000 studies.

Secondary Outcome Measures
NameTimeMethod
Children's healthat 24 months from study entry

Children's health and follow-up data

Pregnancies evolutionAt 24 months from study entry

Pregnancies evolution and outcome, children health and follow-up data according to AIDA0493 and AIDA2000 treatment strategies

Trial Locations

Locations (36)

S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo

🇮🇹

Alessandria, Italy

Azienda Ospedaliera - Nuovo Ospedale "Torrette"

🇮🇹

Ancona, Italy

Unità Operativa Ematologia 1 - Università degli Studi di Bari

🇮🇹

Bari, Italy

Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi

🇮🇹

Bologna, Italy

Ospedali Riuniti di Bergamo

🇮🇹

Bergamo, Italy

Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO

🇮🇹

Bolzano, Italy

Sezione di Ematologia e Trapianti Spedali Civili

🇮🇹

Brescia, Italy

Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia

🇮🇹

Catanzaro, Italy

Sezione di Ematologia C.T.M.O. Istituti Ospitalieri

🇮🇹

Cremona, Italy

Sez.Ematologia e Dip. scienze Biomediche Arcispedale S. Anna

🇮🇹

Ferrara, Italy

Policlinico di Careggi, Università delgi studi di Firenze

🇮🇹

Firenze, Italy

Divisione di Ematologia Ospedale "Santa Maria Goretti"

🇮🇹

Latina, Italy

Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina

🇮🇹

Messina, Italy

Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte"

🇮🇹

Messina, Italy

Ospedale Niguarda " Ca Granda"

🇮🇹

Milano, Italy

U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele

🇮🇹

Milano, Italy

Centro Oncologico Modenese - Dipartimento di Oncoematologia

🇮🇹

Modena, Italy

N. Osp. divisione di Ematologia "S.Gerardo dei Tintori"

🇮🇹

Monza, Italy

Azienda Ospedaliera Universitaria - Università degli Studi di Napoli "Federico II" - Facoltà di Medicina e Chirurgia

🇮🇹

Napoli, Italy

Ospedale S. Gennaro ASL NA1

🇮🇹

Napoli, Italy

Divisione di Ematologia con trapianto di midollo - A.U. Policlinico "Paolo Giaccone"

🇮🇹

Palermo, Italy

Ospedali Riuniti "Villa Sofia-Cervello"

🇮🇹

Palermo, Italy

Cattedra di Ematologia CTMO Università degli Studi di Parma

🇮🇹

Parma, Italy

Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della MIsericordia

🇮🇹

Perugia, Italy

Istituto di Ematologia- Ospedale San Carlo

🇮🇹

Potenza, Italy

Azienda Ospedaliera Bianchi Melacrino Morelli

🇮🇹

Reggio Calabria, Italy

Vulture U.O. di Ematologia - Centro Oncologico Basilicata

🇮🇹

Rionero in Vulture, Italy

Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia

🇮🇹

Roma, Italy

Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza

🇮🇹

San Giovanni Rotondo, Italy

U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte"

🇮🇹

Siena, Italy

U.O.C. di Ematolgia - A.O. " SS Annunziata" - P.O. S.G. Moscati

🇮🇹

Taranto, Italy

SCDO Ematologia 2 AOU S.Giovanni Battista

🇮🇹

Torino, Italy

Clinica Ematologica - Policlinico Universitario

🇮🇹

Udine, Italy

Ospedale San Bortolo

🇮🇹

Vicenza, Italy

Clinica Ematologica - DiMI - Università degli Studi di Genova

🇮🇹

Genova, Italy

Università Cattolica del Sacro Cuore - Policlinico A. Gemelli

🇮🇹

Roma, Italy

© Copyright 2025. All Rights Reserved by MedPath